Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Oncology Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBOT alertsBridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed August 13, 2025 that Pedro Beltran was appointed Chief Scientific Officer, effective May 1, 2024. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed August 13, 2025 that Pedro Beltran was appointed Chief Scientific Officer, effective August 11, 2025. Pedro Beltran has spoken on 1 investor event across 1 company, most recently for BridgeBio Oncology Therapeutics, Inc. on September 15, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro Beltran, Ph.D. (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member) and 7 others.
“On behalf of TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (the “Company”), I am pleased to confirm our offer to employ you as Chief Scientific Officer.”
“Pedro Beltran was appointed as PubCo's Chief Scientific Officer”
“I mean, obviously, we're super excited about what's going on in China. I think it opens, you know, great opportunities for companies like us that are innovating.”
2025-08-11–present
Biotechnology · Healthcare
